BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News → Who are Nvidia’s Silent Partners? (From Weiss Ratings) (Ad) Free ARKG Stock Alerts $25.65 -0.64 (-2.43%) (As of 05/23/2024 ET) Add Compare Share Share Today's Range$25.29▼$26.4350-Day Range$23.01▼$28.8752-Week Range N/AVolume2.83 million shsAverage VolumeN/AMarket Capitalization$1.45 billionAssets Under Management$1.48 billionDividend YieldN/ANet Expense Ratio0.75% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get ARK Genomic Revolution ETF alerts: Email Address About ARK Genomic Revolution ETF (BATS:ARKG)The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.Read More ARKG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARKG ETF News HeadlinesMay 20 at 11:13 PM | markets.businessinsider.comCathie Wood's Ark Invest Buys Shares Of Nvidia-Rival AMD, Continues Its Shopify Share-Buying SpreeMay 16, 2024 | americanbankingnews.comStock Traders Purchase High Volume of Put Options on ARK Genomic Revolution ETF (BATS:ARKG)May 6, 2024 | msn.comArk Invest, Led by Cathie Wood, Acquires $3.54M in Shares of Biopharma Company Post Positive Obesity Pipeline UpdateMay 5, 2024 | msn.comCathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline UpdateApril 23, 2024 | finance.yahoo.comCathie Wood: Macro Environment Will Dictate Launch TimingApril 22, 2024 | fool.com3 Cathie Wood ETFs Just Hit 4-Month Lows. Are They Worth Buying Now?April 17, 2024 | msn.comStandard BioTools (LAB) Price Target Decreased by 10.42% to 3.65April 14, 2024 | nasdaq.comARK Genomic Revolution (ARKG) Enters Oversold TerritorySee More Headlines Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings43 Fund Statistics Assets Under Management$1.48 billion Average Daily Volume$2.77 million Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorThe Bank of NewYork Mellon Corporation AdvisorARK Investment Management LLC CustodianThe Bank of NewYork Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of NewYork Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume9,229 Put Options7,047 Call Options2,182 Miscellaneous Outstanding Shares56,500,000Beta1.99 Creation Unit50,000 Creation Fee$500.00 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Ad Weiss RatingsWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.54%0.56%0.51%Other Expenses0.00%0.72%0.54%0.51%0.58%Total Expense0.75%0.72%0.70%0.68%0.70%Fee Waiver0.00%-0.76%-0.55%-0.34%-0.56%Net Expense0.75%0.59%0.60%0.63%0.58% ARK Genomic Revolution ETF (ARKG) Holdings & ExposureTop 10 ARKG HoldingsTwist Bioscience(NASDAQ:TWST)Holding Weight: 8.20%CRISPR Therapeutics(NASDAQ:CRSP)Holding Weight: 6.68%CareDx(NASDAQ:CDNA)Holding Weight: 6.15%Recursion Pharmaceuticals(NASDAQ:RXRX)Holding Weight: 6.11%Intellia Therapeutics(NASDAQ:NTLA)Holding Weight: 4.36%Schrödinger(NASDAQ:SDGR)Holding Weight: 3.82%Moderna(NASDAQ:MRNA)Holding Weight: 3.70%Ionis Pharmaceuticals(NASDAQ:IONS)Holding Weight: 3.64%Arcturus Therapeutics(NASDAQ:ARCT)Holding Weight: 3.60%Beam Therapeutics(NASDAQ:BEAM)Holding Weight: 3.58%ARKG Sector ExposureARKG Industry ExposureFull Holdings Details Similar ETFsFirst Trust NASDAQ Clean Edge Smart Grid Infrastructure Index FundNASDAQ:GRIDARK Next Generation Internation ETFNYSEARCA:ARKWROBO Global Robotics & Automation ETFNYSEARCA:ROBOBlackRock U.S. Carbon Transition Readiness ETFNYSEARCA:LCTUSPDR S&P 500 ESG ETFNYSEARCA:EFIVInstitutional OwnershipWalleye Trading LLCBought 45,300 shares on 5/17/2024Ownership: 0.000%Comerica BankSold 11,511 shares on 5/17/2024Ownership: 0.008%StemPoint Capital LPSold 5,000 shares on 5/14/2024Ownership: 0.000%Safeguard Investment Advisory Group LLCSold 5,431 shares on 5/13/2024Ownership: 0.022%Longitude Cayman Ltd.Bought 7,000 shares on 5/10/2024Ownership: 0.154%View All Institutional Transactions ARKG ETF - Frequently Asked Questions How have ARKG shares performed in 2024? ARK Genomic Revolution ETF's stock was trading at $32.81 at the start of the year. Since then, ARKG shares have decreased by 21.8% and is now trading at $25.65. View the best growth stocks for 2024 here. What does ARKG invest in? ARK Genomic Revolution ETF is a equity fund issued by ARK. ARKG focuses on theme investments. The fund's investments total to approximately $1.48 billion assets under management. What stocks does ARK Genomic Revolution ETF hold? ARKG invests in 43 holdings. Some of the stocks in their portfolio include Twist Bioscience (TWST), CRISPR Therapeutics (CRSP), CareDx (CDNA), Recursion Pharmaceuticals (RXRX), Intellia Therapeutics (NTLA), Schrödinger (SDGR), Moderna (MRNA), Ionis Pharmaceuticals (IONS), Arcturus Therapeutics (ARCT) and Beam Therapeutics (BEAM). What is the management fee for ARK Genomic Revolution ETF? ARK Genomic Revolution ETF's management fee is 0.75% and has no other recorded expenses or fee waivers. The net expense ratio for ARKG is 0.75%. Who are ARK Genomic Revolution ETF's major shareholders? ARK Genomic Revolution ETF's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BNP Paribas Financial Markets (4.22%), IMC Chicago LLC (0.00%), Commonwealth Equity Services LLC (0.62%), Clearwater Capital Advisors LLC (0.31%), SG Americas Securities LLC (0.22%) and Cambridge Investment Research Advisors Inc. (0.21%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (BATS:ARKG) was last updated on 5/23/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTrade**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis could mean the end of the U.S dollar…Colonial MetalsThis military-backed stock “owns” AI marketPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.